MX2015014198A - Anticuerpos cuyo objetivo es m-csf. - Google Patents

Anticuerpos cuyo objetivo es m-csf.

Info

Publication number
MX2015014198A
MX2015014198A MX2015014198A MX2015014198A MX2015014198A MX 2015014198 A MX2015014198 A MX 2015014198A MX 2015014198 A MX2015014198 A MX 2015014198A MX 2015014198 A MX2015014198 A MX 2015014198A MX 2015014198 A MX2015014198 A MX 2015014198A
Authority
MX
Mexico
Prior art keywords
csf
antibodies
fragments
antibodies targeting
antibody fragments
Prior art date
Application number
MX2015014198A
Other languages
English (en)
Inventor
Francis Dodeller
Robert Rauchenberger
Original Assignee
Morphosys Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphosys Ag filed Critical Morphosys Ag
Publication of MX2015014198A publication Critical patent/MX2015014198A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

Esta divulgación se refiere, en general, a anticuerpos o fragmentos de anticuerpos que se unen específicamente a M-CSF. En particular, se divulgan anticuerpos y fragmentos de anticuerpos que se unen a M-CSF y que inhiben la unión de M-CSF al receptor de M-CSF con una CI50 igual o inferior a 10 pM. La invención también se refiere a ácidos nucleicos, vectores y células hospedadoras capaces de expresar los anticuerpos o fragmentos de estos de la invención, composiciones farmacéuticas que comprenden los anticuerpos o fragmentos de estos y los usos de dichos anticuerpos o fragmentos de estos y composiciones para el tratamiento de enfermedades específicas.
MX2015014198A 2013-04-12 2014-04-11 Anticuerpos cuyo objetivo es m-csf. MX2015014198A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13163542 2013-04-12
PCT/EP2014/057360 WO2014167088A1 (en) 2013-04-12 2014-04-11 Antibodies targeting m-csf

Publications (1)

Publication Number Publication Date
MX2015014198A true MX2015014198A (es) 2015-12-11

Family

ID=48050609

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015014198A MX2015014198A (es) 2013-04-12 2014-04-11 Anticuerpos cuyo objetivo es m-csf.

Country Status (13)

Country Link
US (2) US9856316B2 (es)
EP (1) EP2984106B1 (es)
JP (1) JP2016516092A (es)
KR (1) KR20150140752A (es)
CN (1) CN105121466A (es)
AU (1) AU2014253090B2 (es)
BR (1) BR112015025622A2 (es)
CA (1) CA2907973A1 (es)
EA (1) EA031471B1 (es)
MX (1) MX2015014198A (es)
SG (1) SG11201507871XA (es)
WO (1) WO2014167088A1 (es)
ZA (1) ZA201507251B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170132171A (ko) 2015-02-26 2017-12-01 메르크 파텐트 게엠베하 암 치료를 위한 ｐｄ­１ ／ ｐｄ­ｌ１ 저해제
KR20180018762A (ko) 2015-06-16 2018-02-21 메르크 파텐트 게엠베하 Pd-l1 길항제 조합 치료
US11274154B2 (en) 2016-10-06 2022-03-15 Pfizer Inc. Dosing regimen of avelumab for the treatment of cancer
WO2023246908A1 (zh) * 2022-06-21 2023-12-28 四川大学华西医院 靶向csf1r的嵌合抗原受体免疫细胞制备及其应用
CN115806626B (zh) * 2022-06-21 2024-02-23 四川大学华西医院 一种基于csf1的嵌合抗原受体免疫细胞制备及其应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990009400A1 (en) 1989-02-10 1990-08-23 Cetus Corporation M-csf monoclonal antibodies that recognize a neutralizing conformational epitope
CH686365A5 (de) 1992-10-06 1996-03-15 Werner Hofliger Mobilkran.
US7507705B2 (en) 1997-10-02 2009-03-24 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Methods for the modulation of neovascularization and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
DK1144607T5 (da) 1999-07-20 2009-10-05 Morphosys Ag Fremgangsmåde til præsentation af (poly)peptider/proteiner på bakteriofage partikler via disulfidbindinger
CA2388298C (en) 1999-10-28 2013-05-14 Seyedhossein Aharinejad The use of csf-1 inhibitors
US7108852B2 (en) 2000-03-20 2006-09-19 Warner-Lambert Company Llc Methods of treating inflammation using antibodies to M-CSF
US7455836B2 (en) 2000-05-08 2008-11-25 The University Of Melbourne Method of treatment and agents useful for same
KR20040040489A (ko) 2001-10-15 2004-05-12 카이론 코포레이션 조직 인자 경로 억제제（ｔｆｐｉ）의 저용량 투여에 의한패혈증의 치료
US7771951B2 (en) 2001-12-03 2010-08-10 Amgen Fremont Inc. Antibody categorization based on binding characteristics
SE0200667D0 (sv) 2002-03-05 2002-03-05 A & Science Invest Ab Novel use of cytokine inhibitors
US20110091451A1 (en) 2002-11-15 2011-04-21 Kavanaugh William M Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
CN1787837A (zh) 2002-11-15 2006-06-14 希龙公司 防止和治疗癌转移以及与癌转移相关的骨质损失的方法
AR045563A1 (es) * 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
GB0325836D0 (en) 2003-11-05 2003-12-10 Celltech R&D Ltd Biological products
ES2543833T3 (es) * 2004-01-07 2015-08-24 Novartis Vaccines And Diagnostics, Inc. Anticuerpo monoclonal M-CSF-específico y usos del mismo
DK2620450T3 (en) 2005-03-08 2019-02-04 Pfizer Prod Inc Antibody Compositions against CTLA-4
AU2006270057A1 (en) 2005-07-18 2007-01-25 Trustees Of Boston University Method to inhibit proliferation and growth of metastases
US8652469B2 (en) 2005-07-28 2014-02-18 Novartis Ag M-CSF-specific monoclonal antibody and uses thereof
US20080233118A1 (en) * 2005-07-28 2008-09-25 Novartis Ag Uses Of Antibody To M-Csf
EP2705854A1 (en) 2006-01-05 2014-03-12 Novartis AG Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
US20090010941A1 (en) 2007-04-09 2009-01-08 University Of Massachusetts Methods for treating HIV
DK2188313T3 (en) 2007-08-21 2017-12-11 Amgen Inc HUMAN C-FMS ANTI-BINDING PROTEINS
EP2241333A1 (en) 2007-12-12 2010-10-20 National Cancer Center Therapeutic agent for mll leukemia and moz leukemia of which molecular target is m-csf receptor, and use thereof
GB0725217D0 (en) 2007-12-24 2008-02-06 Reckitt Benckiser Uk Ltd Cleaning device
US8470977B2 (en) 2008-03-14 2013-06-25 Transgene S.A. Antibody against the CSF-1R
WO2010017224A2 (en) 2008-08-05 2010-02-11 University Of South Florida Methods of treating cognitive impairment
RS58693B1 (sr) 2009-12-10 2019-06-28 Hoffmann La Roche Antitela koja poželjno vezuju ekstracelularni domen 4 humanog csf1r, i njihova primena
KR101656548B1 (ko) 2010-03-05 2016-09-09 에프. 호프만-라 로슈 아게 인간 ｃｓｆ-1ｒ에 대한 항체 및 이의 용도
EP2542588A1 (en) 2010-03-05 2013-01-09 F. Hoffmann-La Roche AG Antibodies against human csf-1r and uses thereof
TWI713942B (zh) 2010-05-04 2020-12-21 美商戊瑞治療有限公司 與集落刺激因子１受體（ｃｓｆ１ｒ）結合之抗體類
MX2014005570A (es) * 2011-11-08 2014-05-30 Pfizer El uso de anticuerpos anti factor estimulante de la colonia de macrofagos para tratar trastornos inflamatorios.

Also Published As

Publication number Publication date
US20180057581A1 (en) 2018-03-01
EP2984106B1 (en) 2019-03-06
AU2014253090A1 (en) 2015-10-08
CA2907973A1 (en) 2014-10-16
US9856316B2 (en) 2018-01-02
SG11201507871XA (en) 2015-10-29
US10081675B2 (en) 2018-09-25
KR20150140752A (ko) 2015-12-16
JP2016516092A (ja) 2016-06-02
AU2014253090B2 (en) 2018-10-25
CN105121466A (zh) 2015-12-02
EP2984106A1 (en) 2016-02-17
EA201591898A1 (ru) 2016-03-31
ZA201507251B (en) 2016-12-21
WO2014167088A1 (en) 2014-10-16
BR112015025622A2 (pt) 2017-07-18
EA031471B1 (ru) 2019-01-31
US20160102142A1 (en) 2016-04-14

Similar Documents

Publication Publication Date Title
MX2023000818A (es) Anticuerpos anti-antigeno 4 del linfocito t citotoxico (ctla-4) y metodos para uso de los mismos.
MX2017014908A (es) Proteinas de union triespecificas y metodos de uso.
WO2014160160A3 (en) Antibody drug conjugates and corresponding antibodies
TWI799368B (zh) 抗ｔｌ１ａ抗原結合蛋白及相關核酸、表現載體、宿主細胞、醫藥組合物、方法及用途
TN2015000396A1 (en) Antibody drug conjugates
BR112014028785A2 (pt) proteínas de ligação a antígeno de st2
WO2015109124A3 (en) Immunomodulatory agents
MX359258B (es) Polipeptidos de enlace biparatopicos para cxcr2 y usos de los mismos.
WO2015112886A3 (en) Binding proteins and methods of use thereof
WO2014145159A3 (en) Charge-engineered antibodies or compositions of penetration-enhanced targeting proteins and methods of use
MX2015008446A (es) Composiciones de proteinas de union multivalentes.
WO2015069922A3 (en) Alk antibodies, conjugates, and chimeric antigen receptors, and their use
PH12019500571A1 (en) Anti-pd-1 antibodies
PH12016500275B1 (en) Antibodies
MD20140104A2 (ro) Polipeptide care se leagă de CX3CR1
MX366178B (es) Proteinas de btnl3, acidos nucleicos, y anticuerpos y los usos de los mismos.
MX2015014198A (es) Anticuerpos cuyo objetivo es m-csf.
IN2014DN09717A (es)
WO2015001013A3 (en) Human anti-ifn-alpha antibodies
WO2014151834A3 (en) Methods and compositions relating to anti-ccr7 antigen binding proteins
WO2016063026A3 (en) Selective nav protein binders
MX2015004892A (es) Metodos y composiciones que se relacionan con anticuerpos de receptor anti-il-21.
EA201792665A1 (ru) Антитела против ctla-4 и способы их применения
TN2013000171A1 (en) Cxcr2 binding polypeptides
NZ626296A (en) Compositions and methods for antibodies targeting factor p